<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582462</url>
  </required_header>
  <id_info>
    <org_study_id>ION 957943-CS1</org_study_id>
    <nct_id>NCT03582462</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ION-957943 (IONIS FXI-LRX, a GalNAc Conjugated 2สน-MOE Chimeric Antisense Oligonucleotide Inhibitor of Factor XI) Administered Subcutaneously to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, including
      Factor XI activity and antigen levels, activated partial thromboplastin time, prothrombin
      time and international normalized ratio of single and multiple doses of Factor XI antisense
      inhibitor administered subcutaneously to healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study
      conducted at a single center. The study consists of 4 escalating single-dose cohorts (n = 8
      per cohort, randomized 3 IONIS FXI-LRx active:1 placebo), 3 escalating multiple-dose cohorts
      with weekly Study Drug (IONIS FXI-LRx or placebo) administration for 8 healthy volunteers per
      cohort, randomized 3 active:1 placebo, and 1 multiple-dose cohort of 10 healthy volunteers
      randomized 3 active:2 placebo with Study Drug administration every 4 weeks.

      Approximately 66 healthy volunteers are planned to be enrolled in this study. Additional
      healthy volunteers may be added to better assess the safety, tolerability or pharmacokinetic
      profile of IONIS FXI-LRx to meet study objectives.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Actual">April 26, 2019</completion_date>
  <primary_completion_date type="Actual">April 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability as Measured by the Number of Participants with Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 232 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: maximum observed drug concentration in plasma of IONIS FXI-LRx</measure>
    <time_frame>Up to 232 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: time taken to reach maximal concentration in plasma of IONIS FXI-LRx</measure>
    <time_frame>Up to 232 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC: area under the plasma concentration time curve for IONIS FXI-LRx</measure>
    <time_frame>Up to 232 Days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in Factor XI antigen levels</measure>
    <time_frame>Up to 232 Days</time_frame>
    <description>Factor XI antigen levels will be measured with a reference range of 0.72-1.63 U/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Factor XI activity levels</measure>
    <time_frame>Up to 232 Days</time_frame>
    <description>Factor XI activity levels will be measured with a reference range of 0.73-1.45 U/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Up to 232 Days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in prothrombin time (PT)</measure>
    <time_frame>Up to 232 Days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in the international normalized ratio (INR)</measure>
    <time_frame>Up to 232 Days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>IONIS FXI-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS FXI-LRx</intervention_name>
    <description>Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection</description>
    <arm_group_label>IONIS FXI-LRx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Body mass index (BMI) โค 35 kg/m2

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or
             post-menopausal

          -  Males must be surgically sterile, abstinent or, if engaged in sexual relations with a
             female of child-bearing potential, the subject must be using an acceptable
             contraceptive method from the time of signing the informed consent form until at least
             30 days (single-dose cohorts) or 13 weeks (multiple-dose cohorts) after the last dose
             of Study Drug

          -  Willing to refrain from strenuous exercise/activity for at least 72 hrs prior to study
             visits

          -  Must abstain from alcoholic beverages for at least 48 hrs prior to clinic visits and
             not increase alcohol consumption during the study

        Exclusion Criteria

          -  Clinically-significant abnormalities in medical history, screening laboratory results,
             physical examination that would render a subject unsuitable for inclusion. Including
             but not limited to:

               -  Platelet count &lt; LLN

               -  INR &gt; 1.4

               -  aPTT &gt; ULN

               -  FXI activity &lt; 0.7 U/mL

          -  Treatment with another investigational drug, biological agent, or device within 1
             month of Screening, or 5 half-lives of investigational agent, whichever is longer

          -  Any history of previous treatment with an oligonucleotide

          -  History of bleeding diathesis or coagulopathy

          -  Uncontrolled hypertension (BP &gt; 160/100 mm Hg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BioPharma Services Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9L #A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IONIS FXI-L</keyword>
  <keyword>Factor XI</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

